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Abstract: HLA allele involves along with B-2 microglobulin (B2M) and T cell receptor in host specific immune 
response. HLA alleles are known for its extensive polymorphism in order to accommodate the maximum of 
antigenic peptides. Serum beta-2 microglobulin has been reported to have a prognostic value for predicting disease 
progression in HIV patients. In this study, we evaluated the serum B2M levels and the HLA profile among the 124 
HIV patients and 94 Normal healthy controls from Mumbai. The B2M levels were estimated by conventional 
ELISA technique while the HLA A and HLA B were done using PCR – SSOP molecular kits. Our results revealed 
that HIV patients showed increased B2M levels (88.70%) range (2.5ug/ml – 60ug/ml) compared the controls 
(42.55%). HLA A*11:01:01 (OR=3.25; P value 0.0015), HLA B*35:01:01 OR=3.57;P value 0.0002), HLA 
B*44:03:01 (OR=5.32; P value 0.0036), haplotypes HLA A*11:01:01- B*35:01:01 (OR=5.68; P value 2.47E-05), 
HLA A*33:03:01- B* 44:03:01 (OR=19.95; P value 0.0003) were significantly increased among the B2M increased 
HIV patients. While HLA A*03:01:01:01(OR=0.18; P value 0.0061) was significantly decreased among B2M 
increased HIV patients. Our results reveal that the production of serum B2M levels correlates with the HIV disease 
progression. Therefore it could be of a prognostic value in HIV infection. 
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1. Introduction 
 
Beta-2 microglobulin (B2M) is a protein found on 
the surface of white blood cells. B2M is expressed in all 
nucleated cells of the body and a component of MHC-
class-I molecule. Human B2M is a low molecular 
weight protein (MW 11600) consisting of a single 
polypeptide chain of 99 amino acids present in 
chromosome 15. It is identical to the small chain of the 
HLA-A, -B, and –C Major Histocompatibility complex 
antigens. Levels of native B2M have been used to 
assess renal function in kidney transplant recipients (1). 
It has been suggested that B2M can be used as a 
prognostic marker for HIV infection. B2M is eliminated 
via the kidneys, found at low levels in the serum (Less 
than or equal to 2.7ug/ml) and urine (less than 1ug 24 
hours 0-160ug/ml) of normal individuals. B2M is also 
excreted in increased amounts in the urine of patients 
with upper urinary tract infections and connective-
tissue diseases such as rheumatoid arthritis and 
Sjogren’s syndrome. Serum B2M has prognostic value 
similar to lymphocyte profiles for predicting disease 
progression in HIV infected individuals. Serum B2M 
values among AIDS patients, Intravenous drug users, 
and Pediatric HIV patients has shown a profound 
increase in many studies from African and other 
countries. This study aims to evaluate immune-genetic 
response for beta-2 microglobulin levels among HIV-1 
infected patients and controls. 
 
2. Materials and Methods 
 
A total of 124 HIV-1 infected patients and 94 age 
and sex matched controls were included after KEM 
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ethical committee approval. HIV-1 infected patients 
were confirmed for the HIV infection by rapid, ELISA 
and western blot tests using commercial kits. The 
controls from the same ethnic background had no HIV 
infection. The B2M levels were done using ELISA. The 
molecular HLA A and HLA B typing were done from 
the genomic DNA extracted (2) using PCR-SSOP HLA 
typing reagents the HL alleles were assigned as per the 
kit protocol. The standard statistical analysis was done 
as described (3). 
 
3. Results 
 
Our study revealed increased levels of B2M 
(88.70%) range (2.5ug/ml-60ug/ml) compared to the 
controls (42.55%) (Fig. 1). The HLA distribution 
among the B2M increased patients revealed that HLA 
A*11:01:01, HLA B*35:01:01, HLA B*44:03:01, 
haplotypes A*11:01:01-B*35:01:01, HLA A*33:03:01- 
B*44:03:01 were significantly increased while HLA 
A*03:01:01:01 was significantly decreased (Table 1). 
 
 
Table 1. HLA distribution among B2M positive HIV-1 patients and controls from Mumbai. 
 
HLA Pts (N= 57) Ctls (N=78)       
 % AF % AF OR Ki2 EF PF 95% CI P value  
A*01:01:01 11.40 17.94 0.59 1.71 
  
0.28-1.19 
  A*02:11 19.29 20.51 0.93 0.01   0.50-1.69   A*03:01:01:01 2.63 1.82 0.18 7.52  0.08 0.05-0.63 0.0061 ** A*11:01:01 22.80 8.33 3.25 10.03 0.15  1.58-6.65 0.0015 ** A*24:02:01:01 14.03 10.89 1.34 0.35 0.03  0.64-2.71   A*26:01:01 7.01 1.28 5.81 4.57 0.05  1.21-27.91 0.0325  A*33:03:01 23.68 21.79 1.11 0.05 0.02 
 
0.62-1.98 
  A*68:01:01 2.63 3.21 0.82 0.08   0.19-3.48   B*07:02:01 13.15 14.74 0.88 0.04   0.43-1.76   B*08:01:01 7.01 1.28 5.81 4.57 0.05 
 
1.21-27.91 0.0325 
 B*15:01:01 1.75 1.28 1.40 0.10   0.19-4.91   B*27:05:02 1.75 1.28 1.38 0.10   0.19-9.91   B*35:01:01 28.94 10.25 3.57 14.26 0.20  1.84-6.87 0.0002 ** B*40:06:01:01 21.92 17.30 1.34 0.63 0.05  0.73-2.46   B*44:03:01 12.28 2.56 5.32 8.48 0.09  1.70-16.63 0.0036 ** B*54:01 3.50 1.92 1.86 0.18   0.40-8.46   
B*57:01:01 12.28 16.66 0.70 0.69   0.34-1.41   
Haplotypes % HF % HF OR Ki2 EF PF 95% CI P value  A*01:01:01-B*57:01:01 11.40 16.02 0.67 0.81 
  
.32-1.38 
  A*02:11-B*40:06:01:01 17.54 14.74 1.23 0.21 
  
.63-2.39 
  A*11:01:01-B*35:01:01 21.05 4.48 5.68 16.19 0.17  2.35-13.71 2.47E-05 ** A*24:02:01:01-B*07:02:01 12.28 4.48 2.98 4.54 0.07  1.16-7.64 0.033  A*26:01:01-B*08:01:01 7.01 1.28 5.81 4.57 0.05 
 
1.21-27.91 0.032 
 A*33:03:01-B*44:03:01 11.40 0.64 19.95 13.41 0.10  2.56-154.95 0.0003 ** 
N+ -Number Positive;OR - Odds Ratio; PF- preventive fraction **significant P value; %AF -allele frequency percentage;  
Ki2 -Chi-square with Yates Correction;EF -etiological fraction;95% CI- 95% confidence Interval;%HF -Haplotype frequency percentage 
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4. Discussion 
 
B2M is a protein component of MHC class I 
molecules, present in the surface of all nucleated cells, 
more in lymphocytes. B2M is a plasma protein 
produced by activated lymphocytes, levels increase in 
serum with HIV progressive infection in patients with 
AIDS Dementia complex, possibly another marker for 
HIV progression. Increased production or destruction of 
lymphocytes causes B2M levels to increase in blood. 
The B2M levels are increased among patients with 
progressive infection, like, multiple myeloma, 
connective tissue diseases Rheumatoid arthritis and 
Sjogren’s syndrome (4), EA marker for long-term 
haemodialysed Chronic renal failure patients (5), 
amyloidosis (6), viral infected patients (7) and 
Lymphoproliferative disorders (8). The measurement of 
B2M levels in 369 STD patients, results revealed a 
prognostic value for HIV infection (9).  
Earlier many results on HLA allele associations 
have been reported from India (10, 11 and 12). In the 
current study, we show that the haplotypes HLA 
A*11:01:01-B*35:01:01 and HLA A*33:03:01- 
B*44:03:01 associated increased with B2M serum 
levels from India. 
 
5. Conclusions 
 
Our study revealed that production of serum B2M 
levels correlates with the HIV progression. Therefore, it 
could be of prognostic value in HIV infection in 
developing countries. 
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